Valorization of carbohydrates: dehydration of sorbitol to isosorbide in the presence of acidic zeolites

Currently, the growing interest in the use of biomass as a renewable and sustainable raw material for the production of energy, chemicals and biofuels is driving the development of new catalytic processes and technologies for its conversion. In this context, the transformation of lignocellulosic biomass can lead to a variety of platform chemicals, with a broad spectrum of applications. Sorbitol is one of the useful biomass-derived chemicals that is obtained by catalytic hydrogenation of glucose, which subsequent dehydration and intramolecular cyclization in acid medium gives rise to the formation of isosorbide. This is a high value-added chemical widely used as intermediate in the pharmaceutical industry, additive polymers such as polyethylene terephthalate (PET) and production of biodegradable polymers. Mineral acids such as sulphuric and hydrochloric acids have efficient catalytic properties for dehydration of sorbitol. However, the well-known drawbacks associated to homogeneous catalysis have promoted the studies of heterogeneous catalytic processes. Thus, solid acid catalysts such as zeolites, tetravalent metal phosphates and sulfated copper oxide have been reported as alternative solid catalysts. Nevertheless, sometimes, drastic experimental conditions are required to reach a high catalytic activity. In the present work, different commercial zeolites, in their protonic form, have been evaluated as acid solid catalysts for sorbitol dehydration, and several experimental variables have been optimizedUniversidad de Málaga. Campus de Excelencia Internacional Andalucía Tech. Ministerio de Economía y Competitividad (CTQ2012-38204-C04-02 project), Junta de Andalucía (RNM-1565) y Fondos FEDER de la U

Placental fatty acid transfer: a key factor in fetal growth

The functionality of the placenta may affect neonatal adiposity and fetal levels of key nutrients such as long-chain polyunsaturated fatty acids. Fetal macrosomia and its complications may occur even in adequately controlled gestational diabetic (GDM) mothers, suggesting that maternal glycemia is not the only determinant of fetal glycemic status and wellbeing. We studied in vivo the placental transfer of fatty acids (FA) labeled with stable isotopes administered to 11 control and 9 GDM pregnant women (6 treated with insulin). Subjects received orally &lt;sup&gt;13&lt;/sup&gt;C-palmitic, &lt;sup&gt;13&lt;/sup&gt;C-oleic, and &lt;sup&gt;13&lt;/sup&gt;C-linoleic acids and &lt;sup&gt;13&lt;/sup&gt;C-docosahexaenoic acid (&lt;sup&gt;13&lt;/sup&gt;C-DHA) 12 h before an elective caesarean section. FA were quantified by gas chromatography and &lt;sup&gt;13&lt;/sup&gt;C enrichments by gas chromatography-isotope ratio mass spectrometry. The &lt;sup&gt;13&lt;/sup&gt;C-FA concentration was higher in total lipids of maternal plasma in GDM patients versus controls, except for &lt;sup&gt;13&lt;/sup&gt;C-DHA. Moreover, &lt;sup&gt;13&lt;/sup&gt;C-DHA showed a lower placenta/maternal plasma ratio in GDM patients versus controls and a significantly lower cord/maternal plasma ratio. Other FA ratios studied were not different between GDM and controls. A disturbed &lt;sup&gt;13&lt;/sup&gt;C-DHA placental uptake occurred in GDM patients treated with diet or insulin, while the latter also had lower &lt;sup&gt;13&lt;/sup&gt;C-DHA levels in the venous cord. The tracer study pointed towards an impaired placental DHA uptake as a critical step, while the transfer of other &lt;sup&gt;13&lt;/sup&gt;C-FA was less affected. Patients with GDM treated with insulin could also have a greater fetal fat storage, which may have contributed to the reduced &lt;sup&gt;13&lt;/sup&gt;C-DHA in the venous cord observed. The DHA transfer to the fetus was reduced in GDM pregnancies compared to controls. This might have an influence on fetal neurodevelopment and long-term consequences for the child.</jats:p

Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction

Acute myocardial infarction with ST-segment elevation (STEMI) initiates with intraluminal thrombosis and results in total occlusion of the coronary artery. To date, characterization of the coronary thrombus proteome in STEMI patients has not been yet accomplished. Therefore, we aimed to perform an in-depth proteomic characterization of the human coronary thrombus by means of three different approaches: 2-DE followed by mass spectrometry (MALDI MS/MS), 1-DE combined either with liquid chromatography coupled to mass spectrometry in a MALDI TOF/TOF (LC-MALDI-MS/MS), or in a LTQ-Orbitrap (LC-ESI-MS/MS). This approach allowed us to identify a total of 708 proteins in the thrombus. Expression in coronary thrombi (n=20) of 14 proteins was verified, and the expression of fibrin and 6 cell markers (platelets, monocytes, neutrophils, eosinophils, T-cells and B-cells) quantified by selected reaction monitoring (SRM). A positive correlation of 5 proteins (fermitin homolog 3, thrombospondin-1, myosin-9, beta parvin and ras-related protein Rap-1b) with CD41 was found, pointing out the potential activation of a focal adhesion pathway within thrombus platelets. DIDO1 protein was found to correlate negatively with thrombus fibrin, and was found up-regulated in the plasma of these STEMI patients, which may constitute a starting point for further analyses in the search for biomarkers of thrombosis. BIOLOGICAL SIGNIFICANCE: The proteomic characterization of the human coronary thrombus may contribute to a better understanding of the mechanisms involved in acute coronary syndrome, and thus pave the road for the identification of new therapeutic targets that may help addressing this and other thrombotic diseases. A novel methodology to characterize thrombus composition and expression of a sub-group of proteins is hereby described, which allowed linking protein expression with cellular and ECM matrix composition of the thrombus. Five proteins (fermitin homolog 3, thrombospondin-1, myosin-9, beta parvin and ras-related protein Rap-1b) co-express within the human coronary thrombus with CD41, pointing out the potential activation of a focal adhesion pathway within thrombus platelets during thrombus formation. Besides, the protein death-inducer obliterator 1, found to be expressed within the human coronary thrombus, has been proved to increase in the plasma of STEMI patients, which constitutes an important starting point for further analyses in the search for biomarkers of thrombosis.This work was supported by grants from the Instituto de Salud Carlos III (FIS PI070537, PI11/02239), Fondos Feder, Redes temáticas de Investigación Cooperativa en Salud (RD12/0042/ 0071, RD06/0014/1015), and Fundación para la Investigación Sanitaria de Castilla-La Mancha (FISCAM PI2008-08, PI2008-28, PI2008-52). These results are lined up with the Spanish initiative on the Human Proteome Project (SpHPP). The CNIC is supported by the Spanish Ministerio de Economia y Competitividad and the Fundacion Pro-CNIC. We would like to thank Dr. Gloria Alvarez-Llamas for her kind suggestions for the manuscript; Gemma Barroso from Proteomic Unit, Hospital Nacional de Paraplejicos, for her help and dedication to this work, as well as Veronica Moral and Ana Gallardo from the same Unit, and TamaraSastre andCarmenBermudez for their technical support.S

Indicadores del uso hospitalario de antimicrobianos basados en el consumo.

OBJECTIVE: To identify indicators of hospital use of antimicrobials from the benchmark analysis of consumption data between hospitals at the same level through the collective judgement of a group of experts. METHOD: A committee formed by members of the Spanish Societies of Hospital Pharmacy and Infectious Diseases and Clinical Microbiology prepared a proposal of indicators which was submitted to consensus by a panel of 21 experts on infectious diseases, microbiology and antimicrobial therapy, through a modified Delphi method. The panel underwent two rounds of scores by e-mail. Participants assigned a score from 1 (completely disagree) to 9 (completely agree) to the relevance of each indicator in four dimensions: scientific evidence, efficacy and safety, ecological impact and cost. Scores were processed according to the RAND- UCLA method. An indicator was considered to be relevant if at least one dimension other than cost obtained a median score equal to or higher than 7 without disagreement among the panel. RESULTS: The committee submitted an initial proposal of 14 indicators. After the first round of panel scores, one indicator was ruled out and two were modified for moving on to the second round. Finally, 13 indicators were considered relevant. CONCLUSIONS: Determining indicators of the hospital use of antimicrobial agents based on consumption can allow the antimicrobial stewardship programs to detect any potential problems with the use of antimicrobial agents, and to help guide their efforts in order to implement actions of improvement, as well as to assess the impact of the measures implemented

Smart Solar Micro-exchangers for Sustainable Mobility of University Camps

Publicado el resumen en: https://www.wmcaus.org/files/WMCAUS2020_Book.pdf. Pendiente de publicación de las contribuciones en IOP Conference Series: Materials Science and Engineering.A significant number of universities have several campuses located in urban or rural settings, or with scattered university buildings that require the use of means of transportation. This implies the mobility and potential displacement of a large community of students, professors and researchers. The use of electric bicycles (e-bikes) is an intermediate alternative between the bicycle and electric cars. It can be an important stimulus for the promotion of the decarbonisation of the University Campus, avoiding the traffic congestion and reducing space requirements for parking. This paper presents the smart solar micro-exchanger model managed through a sustainable mobility web platform, applied to the case study of the University of Malaga (Spain). It is a solar charging station for e-bike, whose design is based on the principles of solar architecture (providing great security to e-bike). It managed by a web platform and app that allows the user to make reservations and learn about the savings in CO2 emissions. The system allows performing an aerobic sports activity without sweating problems when you reach the job. The platform also incorporates a database of quiet and safe routes for e-bike users.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tec

Grupo español de cirugía torácica asistida por videoimagen: método, auditoría y resultados iniciales de una cohorte nacional prospectiva de pacientes tratados con resecciones anatómicas del pulmón

Introduction: our study sought to know the current implementation of video-assisted thoracoscopic surgery (VATS) for anatomical lung resections in Spain. We present our initial results and describe the auditing systems developed by the Spanish VATS Group (GEVATS). Methods: we conducted a prospective multicentre cohort study that included patients receiving anatomical lung resections between 12/20/2016 and 03/20/2018. The main quality controls consisted of determining the recruitment rate of each centre and the accuracy of the perioperative data collected based on six key variables. The implications of a low recruitment rate were analysed for '90-day mortality' and 'Grade IIIb-V complications'. Results: the series was composed of 3533 cases (1917 VATS; 54.3%) across 33 departments. The centres' median recruitment rate was 99% (25-75th:76-100%), with an overall recruitment rate of 83% and a data accuracy of 98%. We were unable to demonstrate a significant association between the recruitment rate and the risk of morbidity/mortality, but a trend was found in the unadjusted analysis for those centres with recruitment rates lower than 80% (centres with 95-100% rates as reference): grade IIIb-V OR=0.61 (p=0.081), 90-day mortality OR=0.46 (p=0.051). Conclusions: more than half of the anatomical lung resections in Spain are performed via VATS. According to our results, the centre's recruitment rate and its potential implications due to selection bias, should deserve further attention by the main voluntary multicentre studies of our speciality. The high representativeness as well as the reliability of the GEVATS data constitute a fundamental point of departure for this nationwide cohort

Heterozygous and Homozygous Variants in SORL1 Gene in Alzheimer's Disease Patients: Clinical, Neuroimaging and Neuropathological Findings

In the last few years, the SORL1 gene has been strongly implicated in the development of Alzheimer’s disease (AD). We performed whole-exome sequencing on 37 patients with early-onset dementia or family history suggestive of autosomal dominant dementia. Data analysis was based on a custom panel that included 46 genes related to AD and dementia. SORL1 variants were present in a high proportion of patients with candidate variants (15%, 3/20). We expand the clinical manifestations associated with the SORL1 gene by reporting detailed clinical and neuroimaging findings of six unrelated patients with AD and SORL1 mutations. We also present for the first time a patient with the homozygous truncating variant c.364C>T (p.R122*) in SORL1, who also had severe cerebral amyloid angiopathy. Furthermore, we report neuropathological findings and immunochemistry assays from one patient with the splicing variant c.4519+5G>A in the SORL1 gene, in which AD was confirmed by neuropathological examination. Our results highlight the heterogeneity of clinical presentation and familial dementia background of SORL1-associated AD and suggest that SORL1 might be contributing to AD development as a risk factor gene rather than as a major autosomal dominant gene.This work was supported by the Instituto de Salud Carlos III (PI17/01067) and AGAUR from the Autonomous Catalan Government (2017SGR1134). Dr. Víctor Antonio Blanco-Palmero is supported by the Instituto de Salud Carlos III (ISCIII, Spanish Biomedical Research Institute) through a “Río Hortega” contract (CM18/0095). Dr. Sara Llamas-Velasco is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) through a “Juan Rodés” contract (JR 18/00046).S